|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
價值評估 |
盈利(現時/預測)
-6.18/-0.92
|
企業價值
82.38M
|
資產負債 |
每股賬面淨值
1.45
|
現金流量 |
現金流量率
--
|
損益表 |
收益
5.00M
|
每股收益
--
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘:2024/12/25 00:28 EST
同行比較之報價最少15分鐘延遲
業務概覽
|
|||
Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage. |